


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously presented) A compound of formula (I)



in which:

A represents thiophene, furan, pyrrole, imidazole, thiazole or oxazole;

R¹ represents a phenyl group or a 5- to 7-membered heteroaromatic ring containing one to three heteroatoms selected independently from oxygen, nitrogen or sulfur; said phenyl or heteroaromatic ring being optionally substituted by one or more substituents selected independently from halogen, cyano, nitro, -NR³R⁴, -CONR⁵R⁶, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, -S(O)_mR¹⁰, -S(O)₂NR⁵R⁶, -NR⁸SO₂R¹⁰, C₁-C₆ alkyl, trifluoromethyl, -(CH₂)_nR¹¹, -O(CH₂)_nR¹¹ or -OR¹²;

R^2 represents hydrogen, halogen, cyano, nitro, $-NR^{13}R^{14}$, $-CONR^{15}R^{16}$, $-COOR^{17}$, $-NR^{18}COR^{19}$, $-S(O)_mR^{20}$, $-S(O)_2NR^{15}R^{16}$, $-NR^{18}SO_2R^{20}$, C_1 - C_2 alkyl, trifluoromethyl, C_2 - C_3 alkenyl, C_2 - C_3 alkynyl, trifluoromethoxy, C_1 - C_2 alkoxy or C_1 - C_2 alkanoyl;

X represents oxygen or sulfur;

each of R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} and R^{12} independently represent a hydrogen atom or C_1 - C_6 alkyl;

R^{11} represents $NR^{21}R^{22}$ where R^{21} and R^{22} are independently hydrogen or C_1 - C_6 alkyl optionally substituted by C_1 - C_4 alkoxy; or R^{21} and R^{22} together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^{23} group where R^{23} is hydrogen or C_1 - C_6 alkyl; or R^{11} represents OR^{24} where R^{24} represents C_1 - C_6 alkyl;

each of R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} and R^{20} independently represent a hydrogen atom or C_1 - C_2 alkyl;

m represents an integer 0, 1 or 2;

n represents an integer 2, 3 or 4;

and optical isomers, racemates, and tautomers thereof and pharmaceutically acceptable salts or solvates thereof;

provided that:


when A represents thiophene, furan or pyrrole, then R^1 is not 4-pyridinyl or 3-pyrazolyl;

and

when A represents oxazole, thiazole or imidazole, then R^1 is not 3-pyridinyl or 5-pyrimidyl.

2. (Original) A compound of formula (I), according to claim 1, wherein X represents oxygen.

3. (Previously presented) A compound of formula (I), according to Claim 1, in which the group A is substituted as shown below in formula (Ia), where B and D are selected from CR², S, O and NR²⁵, where R² is as defined in Claim 1 and R²⁵ is hydrogen or C₁-C₆ alkyl:



4. (Previously presented) A compound according to claim 1 in which the ring A is thiophene.

5. (Previously presented) A compound according to claim 1 in which R¹ represents optionally substituted phenyl.

6. (Previously presented) A compound according to claim 1 in which R² represents H or methyl.

7. (Original) A compound according to claim 6 in which R² represents H.

8. (Original) A compound of formula (I), according to claim 1, selected from:

3-[(aminocarbonyl)amino]-5-phenyl-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(4-isobutylphenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(2-thienyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(3-thienyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[2-(dimethylamino)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[2-(dimethylamino)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-2-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-phenyl-3-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[2-(1-morpholinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[2-(1-piperidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[3-(dimethylamino)propoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[2-(dimethylamino)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[2-(1-morpholinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[2-(1-piperidinyl)ethoxy]phenyl}-2-
thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[3-(dimethylamino)propoxy]phenyl}-2-
thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[2-(1-morpholinyl)ethoxy]phenyl}-2-
thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2-
thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[2-(1-piperidinyl)ethoxy]phenyl}-2-
thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[3-(dimethylamino)propoxy]phenyl}-2-
thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-chlorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-methylphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-methoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-fluorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-fluorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-methoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-chloro-4-methoxyphenyl)-3-
thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(2-chlorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-trifluoromethylphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-methyl-4-methoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3,5-dimethoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(2,3-dimethoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-isopropylphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(2-pyridyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-[2-(5-methoxypyridyl)]-4-methyl-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-pyrimidyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(2-pyrazinyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3,4-dichlorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-cyanophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-hydroxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-[2-(1-piperidinyloxy)]phenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-[2-(diethylamino)ethoxy]phenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(2-furyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-trifluoromethyl-5-phenyl-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(2-(4-methylthiazolyl))-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-phenyl-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-methyl-isoxazol-5-yl)-3-thiophenecarboxamide;


2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-trifluoromethylphenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2-pyridyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(3-pyridyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-[5-(2-methoxypyridyl)]-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-[5-(2,4-dimethoxypyrimidyl)]-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(4-methanesulphonylphenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2-(N-t-butoxycarbonyl)pyrrolyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2-(5-cyanothienyl))-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(3,5-dimethyl-isoxazol-4-yl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(3-furyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2-pyrrolyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(5-pyrimidinyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2-(5-chlorothienyl))-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-[2-(5-trifluoromethylpyridyl)]-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-[2-(5-bromopyridyl)]-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2-(5-cyanofuryl))-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(4-[2-(1-piperidinyloxy)]phenyl)-3-
thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(4-[2-(1-(2,2,6,6-tetramethyl)piperidinyloxy)]phenyl)-3-
thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-(thiazol-4-yl-methoxy)phenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(4-[2-(dimethylamino)ethoxy]phenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(4-[2-(diethylamino)ethoxy]phenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(4-[2-(1-morpholinyl)ethoxy]phenyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2-furyl)-3-thiophenecarboxamide;
2-[(aminocarbonyl)amino]-5-(2-(5-methylfuryl))-3-thiophenecarboxamide;
5-[(aminocarbonyl)amino]-2-(3,5-dichlorophenyl)-1,3-oxazole-4-carboxamide;
5-[(aminocarbonyl)amino]-2-(4-trifluoromethylphenyl)-1,3-oxazole-4-carboxamide;
2-[(aminothiocabonyl)amino]-5-phenyl-3-thiophenecarboxamide;
and pharmaceutically acceptable salts and solvates thereof.

9. (Previously presented) A process for the preparation of a compound of formula (I), according to claim 1, which comprises:


(a) reaction of a compound of formula (II):



(II)


wherein A, R¹ and R² are as defined in Claim 1 with an isocyanate (X = O) or an isothiocyanate (X = S); or

(b) reaction of compound of formula (III) with a compound of formula (IV)



wherein A, X, R¹ and R² are as defined in Claim 1 and LG represents a leaving group; or

(c) reaction of compound of formula (V) with a compound of formula (VI)



wherein A, X, R¹ and R² are as defined in Claim 1 and LG represents a leaving group;

and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

10. (Previously presented) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. (Previously presented) A process for the preparation of a pharmaceutical composition which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

12.-19. Canceled

20. (Previously presented) A method of treating an IKK2 mediated disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

21. (Previously presented) A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

22. (Original) A method according to claim 21, wherein the disease is asthma.

23. (Original) A method according to claim 21, wherein the disease is rheumatoid arthritis.

24. (Original) A method according to claim 21, wherein the disease is multiple sclerosis.

25. (Original) A method according to claim 21, wherein the disease is chronic obstructive pulmonary disease.

26. (Previously presented) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 8, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.